Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis

Joseph Maleszewski, Victor M. Orellana, David O. Hodge, Uwe Kuhl, Heinz Peter Schultheiss, Leslie T Jr. Cooper

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. Long-term follow-up data on those with such survival are lacking. Twenty-six patients with biopsy-proved GCM who survived for >1 year without heart transplantation were identified from a multicenter GCM registry. The incidence of death, transplantation, ventricular assist device placement, and histologically proved disease recurrence was ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated. The mean age of the cohort was 54.6 ± 13.9 years (65% women). The mean follow-up duration was 5.5 years starting 1 year after diagnosis. There were 3 deaths (12%), 5 heart transplantations (19%), and 1 ventricular assist device placement (4%). Three histologically confirmed recurrences of GCM (12%) occurred between 1.5 and 8 years after diagnosis. Thirteen of 26 patients experienced a total of 30 heart failure episodes ≥1 year after initial diagnosis. There were 23 episodes of elevated creatinine in 12 patients, 41 infectious events in 13 patients, and 19 episodes of ventricular arrhythmias in 6 patients with a total of 144 years of follow-up. Starting 1 year after GCM diagnosis, the combined rate of death, transplantation, ventricular assist device placement, and GCM recurrence was 47% at 5 years. In conclusion, the risk for GCM recurrence continues to ≥8 years after diagnosis.

Original languageEnglish (US)
Article number21061
Pages (from-to)1733-1738
Number of pages6
JournalAmerican Journal of Cardiology
Volume115
Issue number12
DOIs
StatePublished - Jun 15 2015

Fingerprint

Myocarditis
Giant Cells
Morbidity
Recurrence
Mortality
Heart-Assist Devices
Heart Transplantation
Cardiac Arrhythmias
Heart Failure
Transplantation
Survival
Renal Insufficiency
Registries
Creatinine
Biopsy
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis. / Maleszewski, Joseph; Orellana, Victor M.; Hodge, David O.; Kuhl, Uwe; Schultheiss, Heinz Peter; Cooper, Leslie T Jr.

In: American Journal of Cardiology, Vol. 115, No. 12, 21061, 15.06.2015, p. 1733-1738.

Research output: Contribution to journalArticle

Maleszewski, Joseph ; Orellana, Victor M. ; Hodge, David O. ; Kuhl, Uwe ; Schultheiss, Heinz Peter ; Cooper, Leslie T Jr. / Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis. In: American Journal of Cardiology. 2015 ; Vol. 115, No. 12. pp. 1733-1738.
@article{87fa2070c58b4707b3ac58ba7b4b69b3,
title = "Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis",
abstract = "Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. Long-term follow-up data on those with such survival are lacking. Twenty-six patients with biopsy-proved GCM who survived for >1 year without heart transplantation were identified from a multicenter GCM registry. The incidence of death, transplantation, ventricular assist device placement, and histologically proved disease recurrence was ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated. The mean age of the cohort was 54.6 ± 13.9 years (65{\%} women). The mean follow-up duration was 5.5 years starting 1 year after diagnosis. There were 3 deaths (12{\%}), 5 heart transplantations (19{\%}), and 1 ventricular assist device placement (4{\%}). Three histologically confirmed recurrences of GCM (12{\%}) occurred between 1.5 and 8 years after diagnosis. Thirteen of 26 patients experienced a total of 30 heart failure episodes ≥1 year after initial diagnosis. There were 23 episodes of elevated creatinine in 12 patients, 41 infectious events in 13 patients, and 19 episodes of ventricular arrhythmias in 6 patients with a total of 144 years of follow-up. Starting 1 year after GCM diagnosis, the combined rate of death, transplantation, ventricular assist device placement, and GCM recurrence was 47{\%} at 5 years. In conclusion, the risk for GCM recurrence continues to ≥8 years after diagnosis.",
author = "Joseph Maleszewski and Orellana, {Victor M.} and Hodge, {David O.} and Uwe Kuhl and Schultheiss, {Heinz Peter} and Cooper, {Leslie T Jr.}",
year = "2015",
month = "6",
day = "15",
doi = "10.1016/j.amjcard.2015.03.023",
language = "English (US)",
volume = "115",
pages = "1733--1738",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "12",

}

TY - JOUR

T1 - Long-Term Risk of Recurrence, Morbidity and Mortality in Giant Cell Myocarditis

AU - Maleszewski, Joseph

AU - Orellana, Victor M.

AU - Hodge, David O.

AU - Kuhl, Uwe

AU - Schultheiss, Heinz Peter

AU - Cooper, Leslie T Jr.

PY - 2015/6/15

Y1 - 2015/6/15

N2 - Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. Long-term follow-up data on those with such survival are lacking. Twenty-six patients with biopsy-proved GCM who survived for >1 year without heart transplantation were identified from a multicenter GCM registry. The incidence of death, transplantation, ventricular assist device placement, and histologically proved disease recurrence was ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated. The mean age of the cohort was 54.6 ± 13.9 years (65% women). The mean follow-up duration was 5.5 years starting 1 year after diagnosis. There were 3 deaths (12%), 5 heart transplantations (19%), and 1 ventricular assist device placement (4%). Three histologically confirmed recurrences of GCM (12%) occurred between 1.5 and 8 years after diagnosis. Thirteen of 26 patients experienced a total of 30 heart failure episodes ≥1 year after initial diagnosis. There were 23 episodes of elevated creatinine in 12 patients, 41 infectious events in 13 patients, and 19 episodes of ventricular arrhythmias in 6 patients with a total of 144 years of follow-up. Starting 1 year after GCM diagnosis, the combined rate of death, transplantation, ventricular assist device placement, and GCM recurrence was 47% at 5 years. In conclusion, the risk for GCM recurrence continues to ≥8 years after diagnosis.

AB - Giant cell myocarditis (GCM) is a rare disorder in which survival beyond 1 year without heart transplantation is uncommon. Long-term follow-up data on those with such survival are lacking. Twenty-six patients with biopsy-proved GCM who survived for >1 year without heart transplantation were identified from a multicenter GCM registry. The incidence of death, transplantation, ventricular assist device placement, and histologically proved disease recurrence was ascertained retrospectively. The rates of recurrent heart failure, ventricular arrhythmias, renal failure, and infectious complications were calculated. The mean age of the cohort was 54.6 ± 13.9 years (65% women). The mean follow-up duration was 5.5 years starting 1 year after diagnosis. There were 3 deaths (12%), 5 heart transplantations (19%), and 1 ventricular assist device placement (4%). Three histologically confirmed recurrences of GCM (12%) occurred between 1.5 and 8 years after diagnosis. Thirteen of 26 patients experienced a total of 30 heart failure episodes ≥1 year after initial diagnosis. There were 23 episodes of elevated creatinine in 12 patients, 41 infectious events in 13 patients, and 19 episodes of ventricular arrhythmias in 6 patients with a total of 144 years of follow-up. Starting 1 year after GCM diagnosis, the combined rate of death, transplantation, ventricular assist device placement, and GCM recurrence was 47% at 5 years. In conclusion, the risk for GCM recurrence continues to ≥8 years after diagnosis.

UR - http://www.scopus.com/inward/record.url?scp=84930180141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930180141&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.03.023

DO - 10.1016/j.amjcard.2015.03.023

M3 - Article

VL - 115

SP - 1733

EP - 1738

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 12

M1 - 21061

ER -